garcinia gummi-gutta's effect on polycystic ovary syndrome-induced in rats and its anti-obesity properties

This study evaluated the effects of garcinia gummi-gutta (l.) n.robson (gg) on polycystic ovary syndrome (pco)-induced in rats and its anti-obesity properties. fifteen wistar rats were divided into three groups: control, 10 mg/kg aqueous extract of garcinia gummi-gutta (aegg), and 20 mg/kg aegg. pco was induced using letrozole-oestradiol, confirmed by vaginal smear tests and weight gain. aegg was screened for phenol (125.66±1.07 µg/ml) and flavonoid (102.66 ± 0.38 µg/ml) content, with its highest concentrations at 20 mg/ml. pancreatic lipase inhibition showed aegg’s anti-lipase effect (66.24%) at 100 μg/ml, compared to orlistat (98.7%) at 1 μg/ml. rats received 20 mg/kg of aegg demonstrated the highest significant reduction in body weight (203.8 g ±1.45 sd) and serum luteinizing hormone (lh) levels (1.24 miu/ml) compared to the 10 mg/kg group and control group. anatomical examination showed a normal uterus and reduced ovarian cysts in both aegg-treated groups compared to the control. aegg, particularly at 20 mg/kg, significantly reduced body weight, lh levels, and reproductive anatomy in pco-induced rats, while demonstrating potential anti-obesity effects despite lower lipolytic activity compared to orlistat. the study suggests that aegg at 20 mg/kg offers benefits in managing pco and preventing obesity.